137 related articles for article (PubMed ID: 37774329)
1. Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.
Del Rivero J; Perez K; Kennedy EB; Mittra ES; Vijayvergia N; Arshad J; Basu S; Chauhan A; Dasari AN; Bellizzi AM; Gangi A; Grady E; Howe JR; Ivanidze J; Lewis M; Mailman J; Raj N; Soares HP; Soulen MC; White SB; Chan JA; Kunz PL; Singh S; Halfdanarson TR; Strosberg JR; Bergsland EK
J Clin Oncol; 2023 Nov; 41(32):5049-5067. PubMed ID: 37774329
[TBL] [Abstract][Full Text] [Related]
2. Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study.
Capdevila J; Teulé A; Barriuso J; Castellano D; Lopez C; Manzano JL; Alonso V; García-Carbonero R; Dotor E; Matos I; Custodio A; Casanovas O; Salazar R;
Oncologist; 2019 Jan; 24(1):38-46. PubMed ID: 29794066
[TBL] [Abstract][Full Text] [Related]
3. Initiation of Somatostatin analogues for neuroendocrine tumor patients: a cost-effectiveness analysis.
Rustgi SD; Oh A; Yang JY; Kang D; Wolin E; Kong CY; Hur C; Kim MK
BMC Cancer; 2021 May; 21(1):597. PubMed ID: 34030646
[TBL] [Abstract][Full Text] [Related]
4. Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors in Korea: Literature Review and Expert Opinion.
Yoo C; Oh CR; Kim ST; Bae WK; Choi HJ; Oh DY; Lee MA; Ryoo BY
Cancer Res Treat; 2021 Apr; 53(2):291-300. PubMed ID: 33421978
[TBL] [Abstract][Full Text] [Related]
5. New pharmacologic therapies for gastroenteropancreatic neuroendocrine tumors.
Lawrence B; Gustafsson BI; Kidd M; Modlin I
Gastroenterol Clin North Am; 2010 Sep; 39(3):615-28. PubMed ID: 20951920
[TBL] [Abstract][Full Text] [Related]
6. Management of Functional Pancreatic Neuroendocrine Neoplasms.
Magi L; Marasco M; Rinzivillo M; Faggiano A; Panzuto F
Curr Treat Options Oncol; 2023 Jul; 24(7):725-741. PubMed ID: 37103745
[TBL] [Abstract][Full Text] [Related]
7. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting.
Kulke MH; Siu LL; Tepper JE; Fisher G; Jaffe D; Haller DG; Ellis LM; Benedetti JK; Bergsland EK; Hobday TJ; Van Cutsem E; Pingpank J; Oberg K; Cohen SJ; Posner MC; Yao JC
J Clin Oncol; 2011 Mar; 29(7):934-43. PubMed ID: 21263089
[TBL] [Abstract][Full Text] [Related]
8. Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting.
Singh S; Hope TA; Bergsland EB; Bodei L; Bushnell DL; Chan JA; Chasen BR; Chauhan A; Das S; Dasari A; Del Rivero J; El-Haddad G; Goodman KA; Halperin DM; Lewis MA; Lindwasser OW; Myrehaug S; Raj NP; Reidy-Lagunes DL; Soares HP; Strosberg JR; Kohn EC; Kunz PL;
J Natl Cancer Inst; 2023 Sep; 115(9):1001-1010. PubMed ID: 37255328
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis and management of neuroendocrine tumours.
Cuthbertson DJ; Shankland R; Srirajaskanthan R
Clin Med (Lond); 2023 Mar; 23(2):119-124. PubMed ID: 36958842
[TBL] [Abstract][Full Text] [Related]
10. How I treat neuroendocrine tumours.
Kiesewetter B; Raderer M
ESMO Open; 2020 Aug; 5(4):. PubMed ID: 32817134
[TBL] [Abstract][Full Text] [Related]
11. Systemic Therapy for Pancreatic Neuroendocrine Tumors.
Lavingia V; Gohel S; Sirohi B
Indian J Surg Oncol; 2024 May; 15(Suppl 2):305-314. PubMed ID: 38817994
[TBL] [Abstract][Full Text] [Related]
12. Current and emerging strategies for the management of advanced/metastatic lung neuroendocrine tumors.
Rutherford M; Wheless M; Thomas K; Ramirez RA
Curr Probl Cancer; 2024 Apr; 49():101061. PubMed ID: 38281845
[TBL] [Abstract][Full Text] [Related]
13. Advancements in medical treatment for pancreatic neuroendocrine tumors: A beacon of hope.
Giri S; Sahoo J
World J Gastroenterol; 2024 Mar; 30(12):1670-1675. PubMed ID: 38617746
[TBL] [Abstract][Full Text] [Related]
14. ONCOGENE PANEL SEQUENCING ANALYSIS IDENTIFIES CANDIDATE ACTIONABLE GENES IN ADVANCED WELL-DIFFERENTIATED GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS.
Tirosh A; Killian JK; Zhu YJ; Petersen D; Walling J; Mor-Cohen R; Neychev V; Stevenson H; Keutgen XM; Patel D; Nilubol N; Meltzer P; Kebebew E
Endocr Pract; 2019 Jun; 25(6):580-588. PubMed ID: 30865533
[No Abstract] [Full Text] [Related]
15. Systemic Treatment Selection for Patients with Advanced Pancreatic Neuroendocrine Tumours (PanNETs).
Megdanova-Chipeva VG; Lamarca A; Backen A; McNamara MG; Barriuso J; Sergieva S; Gocheva L; Mansoor W; Manoharan P; Valle JW
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32708210
[TBL] [Abstract][Full Text] [Related]
16. Everolimus in the management of metastatic neuroendocrine tumours.
Chan DL; Segelov E; Singh S
Therap Adv Gastroenterol; 2017 Jan; 10(1):132-141. PubMed ID: 28286565
[TBL] [Abstract][Full Text] [Related]
17. Responses to Medical Treatment in 192 Patients with Pancreatic Neuroendocrine Neoplasms Referred to the Copenhagen Neuroendocrine Tumour Centre in 2000-2020.
Petersen SS; Møller S; Slott C; Krogh J; Hansen CP; Kjaer A; Holmager P; Oturai P; Garbyal RS; Langer SW; Knigge U; Andreassen M
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539524
[TBL] [Abstract][Full Text] [Related]
18. Meta-Analysis of Randomized Clinical Trials Comparing Active Treatment with Placebo in Metastatic Neuroendocrine Tumors.
Capdevila J; Hernando J; Perez-Hoyos S; Roman-Gonzalez A; Grande E
Oncologist; 2019 Dec; 24(12):e1315-e1320. PubMed ID: 31332100
[TBL] [Abstract][Full Text] [Related]
19. [Current developments in the treatment of neuroendocrine tumors].
Kiesewetter-Wiederkehr B; Melhorn P; Scheuba C; Raderer M
Radiologie (Heidelb); 2024 Apr; ():. PubMed ID: 38649498
[TBL] [Abstract][Full Text] [Related]
20. Emerging use of everolimus in the treatment of neuroendocrine tumors.
Gajate P; Martínez-Sáez O; Alonso-Gordoa T; Grande E
Cancer Manag Res; 2017; 9():215-224. PubMed ID: 28684922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
